Consider 505(b)(2) Pathway [Design Issues]

posted by bebac_fan – US, 2018-05-05 17:08 (1357 d 02:28 ago) – Posting: # 18756
Views: 2,459

I think this would need to go through a NDA/505(b)(2) pathway rather than an ANDA.

In this case, comparative efficacy, rather than BE, will be considered pivotal.

Complete thread:

Activity
 Admin contact
21,833 posts in 4,568 threads, 1,554 registered users;
online 8 (0 registered, 8 guests [including 4 identified bots]).
Forum time: Friday 18:37 CET (Europe/Vienna)

No problem can stand the assault of sustained thinking.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5